Cart
sales@molnova.com
Aurantiamide
CAS No. 58115-31-4
Aurantiamide( TMC-58B )
Catalog No. M20469 CAS No. 58115-31-4
Aurantiamide has anti-cancer anti-inflammatory and antinociceptive activities it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB JNK and p38 pathways.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 468 | In Stock |
|
| 5MG | 330 | In Stock |
|
| 10MG | 489 | In Stock |
|
| 25MG | 782 | In Stock |
|
| 50MG | 1014 | In Stock |
|
| 100MG | 1386 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAurantiamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionAurantiamide has anti-cancer anti-inflammatory and antinociceptive activities it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB JNK and p38 pathways.
-
DescriptionAurantiamide has anti-cancer anti-inflammatory and antinociceptive activities it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB JNK and p38 pathways.
-
In Vitro——
-
In Vivo——
-
SynonymsTMC-58B
-
PathwayApoptosis
-
TargetNF-κB
-
RecptorNF-κB|p38
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number58115-31-4
-
Formula Weight402.5
-
Molecular FormulaC25H26N2O3?
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yoon C S Kim D C Lee D S et al. Anti-neuroinflammatory effect of aurantiamide acetate from the marine fungus Aspergillus sp. SF-5921: Inhibition of NF-κB and MAPK pathways in lipopolysaccharide-induced mouse BV2 microglial cells[J]. International Immunopharmacology 2014 23(2):568-574.
molnova catalog
related products
-
DRI-C21045
Dri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM.
-
BML-190
BML-190 is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor.
-
Iguratimod
A novel disease-modifying antirheumatic drug that inhibits NF-kappaB (NF-κB) p65 subunit (RelA) phosphorylation and nuclear translocation without affecting IKBα degradation.
